Cover Image
市場調查報告書

骨髓性白血病細胞分化誘導蛋白質Mcl-1:開發中產品分析

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 409619
出版日期 內容資訊 英文 65 Pages
訂單完成後即時交付
價格
Back to Top
骨髓性白血病細胞分化誘導蛋白質Mcl-1:開發中產品分析 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Pipeline Review, H1 2018
出版日期: 2018年01月18日 內容資訊: 英文 65 Pages
簡介

本報告提供以骨髓性白血病細胞分化誘導蛋白質Mcl-1為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供你涵括最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

骨髓性白血病細胞分化誘導蛋白質Mcl-1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AbbVie Inc
  • Amgen Inc.
  • AstraZeneca Plc
  • Complix NV
  • Les Laboratoires Servier SAS
  • 武田藥品工業

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1245TDB

Summary:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease), Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Hematological Tumor, Malignant Mesothelioma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Ovarian Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Solid Tumor and T-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
  • The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Overview
    • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Amgen Inc
    • AstraZeneca Plc
    • Complix NV
    • Les Laboratoires Servier SAS
    • Takeda Pharmaceutical Co Ltd
    • Warp Drive Bio Inc
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Drug Profiles
    • AMG-176 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-5991 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-63845 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-64315 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL1 for Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit MCL1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMI-77 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Dormant Products
  • Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 14, 2017: Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies against intracellular cancer targets
      • Aug 03, 2017: Targeting Cancers Achilles Heel To Improve Breast Cancer Treatment
      • Mar 31, 2017: Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
      • Oct 20, 2016: New compound shows promise in treating multiple human cancers
      • Oct 13, 2016: Ascentage Pharma takes a leading position in novel drug development targeting dual pathways of apoptosis and autophagy
      • Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies
      • Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
      • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
      • Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
      • Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent
      • Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent
      • Jun 01, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting
      • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung Cancers At 2009 Asco Annual Meeting
      • Jun 01, 2009: Ascenta Therapeutics Announces Presentation Of Promising Results From Clinical Trials Of AT-101 In Prostate, Brain, And Lung cancers At 2009 Asco Annual Meeting
      • May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AbbVie Inc, H1 2018
  • Pipeline by Amgen Inc, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by Complix NV, H1 2018
  • Pipeline by Les Laboratoires Servier SAS, H1 2018
  • Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
  • Pipeline by Warp Drive Bio Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top